Healthcare
Form 8.5 (EPT/RI)-Advanced Medical Solutions Group Plc
FORM 8.5 (EPT/RI)
Jul 15 · 08:26GlobeNewswire
2,742 press releases indexed under healthcare.
FORM 8.5 (EPT/RI)
Norwalk, USA, 2026-07-15 — /EPR Network/ — Beautiful skin is more than a trend. It is a reflection of healthy care and self-confidence. Lzur Day [read full press release...]
Dr. David B. Hardin of Noblesville, Indiana has been named Professional of the Year for Healthcare, Rehabilitation, and Wound Care by Strathmore's Who's Who Worldwide for his outstanding contributions and achievements in his field. About Dr. David B. Hardin Dr. David B. Hardin is a physician serving patients through his medical practice in Indiana, offering patient care and related services. With more than four decades [PR.com]
Research collaboration highlights safe surgical outcomes and significant health improvements in young patients in Louisiana [PR.com]
Continuous smartwatch monitoring shown to safely support post-surgical care, reducing disruptions for patients and easing nursing time for direct patient care SINGAPORE, July 14, 2026 /PRNewswire/ -- The National University Hospital (NUH) is set to expand the use of wearable technology...
Der Bericht hebt saubere Energie, Innovation und ESG-Anerkennung hervor ZIBO, China, 15. Juli 2026 /PRNewswire/ -- INTCO Medical („das Unternehmen"), ein weltweit führender Hersteller von Einweghandschuhen, hat seinen ESG-Bericht (Umwelt, Soziales und Unternehmensführung) für 2025...
Basel, 15 July 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has granted Priority Review to the company’s supplemental Biologics License Application (sBLA) for Gazyva®/Gazyvaro® (obinutuzumab) for the treatment of primary membranous nephropathy (pMN). The priority review is based on the positive phase III MAJESTY results, which show superiority of Gazyva/Gazyvaro over an immunosuppressive therapy, tacrolimus, in adults with pMN. 1 The FDA has already granted Breakthrough Therapy Designation (BTD) to Gazyva/Gazyvaro in pMN and is expected to make a decision on approval by November 2026. This is the second indication in recent months for which the US FDA has granted priority review to Gazyva/Gazyvaro, following idiopathic nephrotic s
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., July 15, 2026 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today highlights its approaches to overcoming target limitations in radioligand therapy (RLT) through Radio-DARPins, in a presentation at the Gordon Research Conference Radionuclide Theranostics for the Management of Cancer in Newry, Maine, US.
This Gorgeous Grandma Day, Lake Park Dental in Milwaukee spotlights how modern, metal-free implants help women 55 and up smile with confidence again. The post Lake Park Dental Celebrates Gorgeous Grandma Day With a Toast to Milwaukee Smiles first appeared on
MONTREAL, July 14, 2026 (GLOBE NEWSWIRE) -- PREMIER HEALTH OF AMERICA INC. (TSX-V: PHA) (“ Premier Health” or the “Company” ) announces that, in connection with the restructuring proceedings initiated on June 23, 2026 by the Royal Bank of Canada (the “ Applicant ”) in its capacity as a secured creditor (the “ CCAA Proceedings ”) and the Court-approved restructuring transaction announced on July 3, 2026, Polar Valley Investments Limited (“ Polar ”) has successfully closed the acquisition of all of the equity interests in three affiliates of the Company, namely Solutions Staffing Inc. (“ SSI ”), Canadian Health Care Agency Ltd. (“ CHCA ”) and Premier Soin Nordik Inc. / Premier Health Nordik Inc. (“ Nordik Québec ”) (the “ Transaction ”).
WALTHAM, Mass., July 14, 2026 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB), ("Q32 Bio") a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata and other autoimmune and inflammatory diseases, today announced the pricing of an underwritten...
As consumers look beyond demanding daily hair and skincare regimens, this QUINT review explores why Q.SCALP and Q.FACE are attracting attention, how the brand positions its once-monthly exosome-serum systems, and what buyers should confirm about pricing, subscriptions, FDA status, and guarantee terms before ordering.